Story · Health Tech · Products
Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal
1 outlet · first reported by MedCity News on
Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform… (MedCity News)
Coverage, in order
-
Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna DealPfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.